PLC
ANTX icon

Peapod Lane Capital’s AN2 Therapeutics ANTX Stock Holding History

Peapod Lane Capital’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59,854
Closed -$207K – 62
2026
Q1 		$207K Sell
59,854
-533,542
-90% -$1.1M 0.17% 62
2025
Q4 		$676K Buy
593,396
+4,180
+0.7% +$4.88K 0.58% 54
2025
Q3 		$748K Buy
589,216
+6,446
+1% +$7.37K 0.67% 52
2025
Q2 		$618K Buy
582,770
+1,917
+0.3% +$2.29K 0.62% 50
2025
Q1 		$790K Buy
580,853
+2,028
+0.4% +$2.55K 0.89% 41
2024
Q4 		$799K Buy
+578,825
New +$702K 0.79% 50

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Peapod Lane Capital's ANTX Position: Q2 2026 in Review

Peapod Lane Capital sold out of AN2 Therapeutics (ANTX) in Q2 2026, closing a stake of 59,854 shares — an estimated $207K sold.

Peapod Lane Capital first reported a position in ANTX in Q4 2024 and held it in 6 quarters. The position peaked at $799K in Q4 2024. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Peapod Lane Capital reported no remaining AN2 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Peapod Lane Capital sold 59,854 AN2 Therapeutics shares in Q2 2026, an estimated $207K.
  • Peapod Lane Capital first reported a position in AN2 Therapeutics in Q4 2024 and held it in 6 quarters.
  • Peapod Lane Capital's AN2 Therapeutics position peaked at $799K in Q4 2024.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Peapod Lane Capital's 13F filing for Q2 2026, filed 27 Jul 2026.